- Home
- RFIL vs DTIL Comparison
RFIL vs DTIL Comparison
Compare RFIL & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | DTIL |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 214.7M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RFIL | DTIL |
|---|---|---|
| Price | $10.07 | $7.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.25 | ★ $45.00 |
| AVG Volume (30 Days) | 176.4K | ★ 260.1K |
| Earning Date | 06-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $55,325,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $9.65 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | $143.71 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $5.54 | $3.53 |
| 52 Week High | $22.30 | $9.62 |
Technical Indicators
Market Signals| Indicator | RFIL | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 41.87 |
| Support Level | $9.57 | $7.18 |
| Resistance Level | $13.59 | $7.92 |
| Average True Range (ATR) | 0.57 | 0.46 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 2.38 | 9.52 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).